Literature DB >> 33840568

Clinical Management of Olecranon Bursitis: A Review.

Nzuekoh N Nchinda1, Jennifer Moriatis Wolf2.   

Abstract

Olecranon bursitis is a disease characterized by inflammation of the olecranon bursa, most often due to microtrauma. Although it is a common condition, there is a lack of evidence-based recommendations for the management of nonseptic olecranon bursitis. The condition is often self-limited and resolves with conservative methods such as rest, ice, compression, orthosis wear, and nonsteroidal anti-inflammatory medications. Older studies have shown resolution of symptoms with intrabursal corticosteroid injections and surgical bursectomy. More recent literature has demonstrated adverse effects of intrabursal injections and surgery compared with noninvasive management for initial treatment of nonseptic olecranon bursitis. In order to better tailor decision-making, it is important that hand surgeons understand the comparative efficacies of each option for management of nonseptic olecranon bursitis.
Copyright © 2021 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspiration; bursectomy; olecranon bursitis

Year:  2021        PMID: 33840568     DOI: 10.1016/j.jhsa.2021.02.006

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  3 in total

1.  The utility of routine cultures, cell count, and crystal evaluation of aspirate from aseptic olecranon bursitis.

Authors:  Sebastian Bustamante; Michael Boin; John Dankert; David Adekanye; Mandeep S Virk
Journal:  JSES Int       Date:  2022-03-18

2.  Olecranon Bursitis Secondary to Trauma.

Authors:  Shalini Subramanian; Trilok G Stead; Rohan K Mangal; Vashun Rodriguez; Latha Ganti
Journal:  Cureus       Date:  2022-07-26

Review 3.  Inflammatory arthritis and the elbow surgeon.

Authors:  Cameron Dott; Kuen Chin; Jon Compson
Journal:  J Clin Orthop Trauma       Date:  2021-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.